AUGTYRO (Bristol-Myers Squibb Australia Pty Ltd)
Product name
AUGTYRO
Date registered
Evaluation commenced
Decision date
Approval time
245 (255 working days)
Active ingredients
repotrectinib
Registration type
NCE/ NBE
Indication
AUGTYRO, as monotherapy, is indicated for the treatment of adult patients with ROS1- positive locally advanced or metastatic non-small cell lung cancer (NSCLC).